HIGH SUSTAINED VIROLOGICAL RESPONSE RATES WITH RESPONSE-GUIDED DANOPREVIR PLUS PEGINTERFERON ALFA-2A (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE, HCV GENOTYPE 1 PATIENTS: ATLAS STUDY FINAL RESULTS

被引：3
|
作者：
Marcellin, P. [1 ]
Cooper, C. [2 ]
Balart, L. A. [3 ]
Larrey, D. G. [4 ]
Box, T. D. [5 ]
Yoshida, E. [6 ]
Lawitz, E. [7 ]
Buggisch, P. [8 ]
Ferenci, P. [9 ]
Weltman, M. [10 ]
Labriola-Tompkins, E. [11 ]
Le Pogam, S. [11 ]
Najera, I. [11 ]
Thomas, D. N. [11 ]
Hooper, G. [12 ]
Shulman, N. [13 ]
Zhang, Y. [13 ]
Navarro, M. T. [13 ]
Lim, C. Y. [13 ]
Brunda, M. [11 ]
Yetzer, E. S. [13 ]
Terrault, N. [14 ]
机构：
[1] Hop Beaujon, Clichy, France
[2] Ottawa Hosp, Div Infect Dis, Ottawa, ON, Canada
[3] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA
[4] Montpellier Sch Med, Montpellier, France
[5] Univ Utah, Hlth Sci Ctr, Salt Lake City, UT USA
[6] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[7] Alamo Med Res, San Antonio, TX USA
[8] Asklepiosklin St Georg, Hamburg, Germany
[9] Med Univ Vienna, Vienna, Austria
[10] Nepean Hosp, Penrith, NSW, Australia
[11] Roche, Nutley, NJ USA
[12] Roche, Welwyn Garden City, England
[13] Genentech Inc, San Francisco, CA 94080 USA
[14] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61204-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1192
引用
收藏
页码：S472 / S472
页数：1
相关论文
共 50 条
  • [1] RESPONSE-GUIDED THERAPY WITH BOCEPREVIR PLUS PEGINTERFERON ALFA-2a (40KD) AND RIBAVIRIN IN TREATMENT-NAIVE PATIENTS INFECTED WITH HCV GENOTYPE 1: INTERIM RESULTS FROM THE TriCo STUDY
    Ferenci, P.
    Flisiak, R.
    Caruntu, F. A.
    Lengyel, G.
    Hohmann, M.
    Bakalos, G.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S453 - S454
  • [2] Treatment with peginterferon alfa-2a (40kd) and ribavirin in older HCV genotype 1 patients with positive prognostic factors leads to high rates of sustained virological response
    Reddy, K. R.
    Messinger, D.
    Popescu, M.
    Hadziyanni, S. J.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S310 - S310
  • [3] Peginterferon alfa-2a (40KD) (Pegasys®) plus ribavirin (Copegus®) for HCV genotype I patients:: Predicting sustained virological response (SVR) rates and anemia
    Snoeck, Eric
    Wade, Janet
    Lamb, Matthew
    Duff, Frank
    Grippo, Joseph
    Jorga, Karin
    GASTROENTEROLOGY, 2006, 130 (04) : A840 - A841
  • [4] HIGH SUSTAINED VIROLOGIC RESPONSE RATES IN HCV GENOTYPE 1 RELAPSER PATIENTS RETREATED WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN FOR 72 WEEKS
    Kaiser, Stephan
    Lutze, Bettina
    Hass, Holer G.
    Werner, Christoph R.
    HEPATOLOGY, 2008, 48 (04) : 1140A - 1140A
  • [5] A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin
    Ferenci, Peter
    Aires, Rodrigo
    Ancuta, Ioan
    Arohnson, Andrew
    Cheinquer, Hugo
    Delic, Dragan
    Gschwantler, Michael
    Larrey, Dominique
    Tallarico, Ludovico
    Schmitz, Manuela
    Tatsch, Fernando
    Ouzan, Denis
    LIVER INTERNATIONAL, 2014, 34 (10) : 1550 - 1559
  • [6] HIGH SUSTAINED VIROLOGIC RESPONSE (SVR24) RATES WITH RESPONSE-GUIDED DANOPREVIR (DNV; RG7227) PLUS PEGIFN α-2A (40KD) AND RIBAVIRIN (P/R) IN TREATMENT-NAIVE HCV GENOTYPE 1 (G1) PATIENTS: RESULTS FROM THE ATLAS STUDY
    Terrault, Norah
    Cooper, Curtis
    Balart, Luis A.
    Larrey, Dominique G.
    Box, Terry D.
    Yoshida, Eric
    Lawitz, Eric
    Buggisch, Peter
    Ferenci, Peter
    Weltman, Martin
    Labriola-Tompkins, Emily
    Thomas, Denise N.
    Hooper, Greg
    Shulman, Nancy
    Zhang, Ying
    Navarro, Mercidita T.
    Lim, Chin Yin
    Yetzer, Ellen S.
    Marcellin, Patrick
    HEPATOLOGY, 2011, 54 : 398A - 399A
  • [7] Response-guided therapy in a prospective trial of peginterferon alfa-2a(40KD)/ribavirin treatment in patients with genotypes 1 or 4
    Ferenci, Peter
    Laferl, Hermann
    Scherzer, Thomas-Matthias
    Brunner, Harald
    Maieron, Andreas
    Gschwantler, Michael
    Stauber, Rudolf E.
    Hubmann, Rainer
    Staufer, Katharina
    Datz, Christian
    Bischof, Martin
    Hofer, Harald
    Loeschenberger, Karin
    Steindl-Munda, Petra E.
    HEPATOLOGY, 2007, 46 (04) : 814A - 815A
  • [8] Sustained virological response (SVR) to peginterferon alfa-2A (40kd) (Pegasys®) plus ribavirin (Copegus®):: Comparison of outcomes in patients infected with HCV genotype 2 and 3.
    Rizzetto, M
    Hadziyannis, SJ
    Ackrill, AM
    HEPATOLOGY, 2004, 40 (04) : 252A - 252A
  • [9] Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin
    Snoeck, Eric
    Wade, Janet R.
    Duff, Frank
    Lamb, Matthew
    Jorga, Karin
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (06) : 699 - 709
  • [10] RESPONSE-GUIDED THERAPY WITH PEGINTERFERON ALFA-2A (40KD) PLUS RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS C GENOTYPE 1 OR 4: PROSPECTIVE RANDOMIZED STUDY OF EXTENDED THERAPY IN PATIENTS WITHOUT A RAPID VIROLOGICAL RESPONSE
    Ferenci, Peter
    Laferl, Hermann
    Scherzer, Thomas-Matthias
    Gschwantler, Michael
    Maieron, Andreas
    Brunner, Harald
    Stauber, Rudolf E.
    Bischol, Martin
    Bauer, Bernhard
    Datz, Christian
    Loeschenberger, Karin
    Formann, Elisabeth
    Hofer, Harald
    Steindl-Munda, Petra E.
    HEPATOLOGY, 2008, 48 (04) : 357A - 357A
12345